M
Martin J. Glennie
Researcher at University of Southampton
Publications - 204
Citations - 17101
Martin J. Glennie is an academic researcher from University of Southampton. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 64, co-authored 200 publications receiving 15908 citations. Previous affiliations of Martin J. Glennie include University of Stirling & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Guidelines for the welfare and use of animals in cancer research
Paul Workman,Eric O. Aboagye,Frances R. Balkwill,Allan Balmain,G Bruder,D.J. Chaplin,John A. Double,Jeffrey I. Everitt,D A H Farningham,D A H Farningham,Martin J. Glennie,Lloyd R. Kelland,V Robinson,Ian J. Stratford,Gillian M. Tozer,Susan A. Watson,Stephen R. Wedge,Suzanne A. Eccles,V Navaratnam,S Ryder +19 more
TL;DR: New guidelines on the welfare and use of animals in cancer research are provided, including recommendations on all aspects of cancer research, including: study design, statistics and pilot studies; choice of tumour models and humane endpoints.
Journal ArticleDOI
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Jessica L. Teeling,Ruth R. French,Mark S. Cragg,Jeroen van den Brakel,Marielle Pluyter,Haichun Huang,Claude H.T. Chan,Paul W. H. I. Parren,C. Erik Hack,Michael Dechant,Thomas Valerius,Jan G. J. van de Winkel,Martin J. Glennie +12 more
TL;DR: With increasing evidence that mAb therapeutic activity in vivo depends on complement activation, these new CD20 reagents with their slow off-rates and increased potency in CDC hold considerable promise for improved clinical activity.
Journal ArticleDOI
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Jessica L. Teeling,Wendy J.M. Mackus,Luus Wiegman,Jeroen van den Brakel,Stephen A. Beers,Ruth R. French,Tom van Meerten,Saskia B. Ebeling,Tom Vink,Jerry W. Slootstra,Paul W. H. I. Parren,Martin J. Glennie,Jan G.J. van den Winkel,Jan G.J. van den Winkel +13 more
TL;DR: It is concluded that recognition of the novel epitope cooperates with slow off-rate in determining the activity of CD20 Ab in activation of complement and induction of tumor cell lysis.
Journal ArticleDOI
Immunostimulatory monoclonal antibodies for cancer therapy
TL;DR: Promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies, and mAbs of this type have now entered clinical trials with encouraging initial results.
Journal ArticleDOI
Mechanisms of killing by anti-CD20 monoclonal antibodies.
TL;DR: How monoclonal antibodies (mAb) have driven research in the immunotherapy field over the last decade are discussed, their likely modes of action and their limitations in terms of effector exhaustion are explored, and ways in which they might be enhanced and further exploited in the future are explored.